Integrase inhibitors in salvage therapy regimens for HIV-1 infection

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 518-523

  Koelsch, Kersten K ^a,b   Cooper, David A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Elvitegravir; HIV; Integrase inhibitors; Raltegravir; Therapy

Indexed keywords

ANTIVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; GS 9350; GSK 1349572; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MK 0248; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; VIRUS LOAD; VIRUS REPLICATION;

HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; QUINOLONES; SALVAGE THERAPY;

EID: 70350154011     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328331b526     Document Type: Review

References (25)

1. Cox S, Southby J. Apricitabine: a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Expert Opin Investig Drugs 2009; 18:199-209.
2. Mewshaw JP, Myrick FT, Wakefield DA, et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drugresistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J Acquire Immune Defic Syndr 2002; 29:11-20.
3. Murphy R, Zala C, Ochoa C, et al. Pharmacokinetics and potent anti-HIV-1 activity of amdoxovir plus zidovudine in a randomized double-blind placebocontrolled study. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008. Boston. Abstract 794.
4. Margolis DM, Mukherjee AL, Fletcher CV, et al. The use of beta-D-2,6- diaminopurine dioxolane with or without mycophenolate mofetil in drugresistant HIV infection. AIDS 2007; 21:2025-2032.
5. De Jesus E, et al. Elvucitabine phase II 48 week interim results show safety and efficacy profiles similar to lamivudine in treatment nayve HIV-1 infected patients with a unique pharmacokinetic profile. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract H-892, Washington, 2008.
6. Colucci P, Pottage JC, Robison H, et al. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother 2009; 53:646-650.
7. Colucci P, Pottage JC, Robison H, et al. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob Agents Chemother 2009; 53:662-669.
8. Cahn P, Sosa N, Wiznia A, et al. (racivir 201 Study Team). Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and >3 TAM 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007 Los Angeles, California. Abstract 488
9. Fätkenheuer G, Staszweski S, Plettenberg A, et al. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV infected patients. Presented at: The International AIDS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney.
10. Xu W, Zhang Z, Bellows D, et al. Resistance to RDEA806 requires multiple mutations which have limited cross-resistance to other NNRTIs. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008). Washington, DC. 25-28 October 2008. Abstract H-1222.
11. Moyle G, Boffito M, Manhard K, et al. Antiviral activity of RDEA806, a novel HIV nonnucleoside reverse transcriptase inhibitor in treatment naive HIV patients. XVII International AIDS Conference (AIDS 2008). Mexico City. 3-8 August 2008. Abstract THAB0403.
12. Zhou XJ, Pietropaolo K, Damphousse D, et al. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009; 53:1739-1746.
13. Zala C, Murphy R, Zhou X-J, et al. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naive HIV-1-infected subjects. XVII International AIDS Conference (AIDS 2008). Mexico City. 3-8 August 2008. Abstract THAB0402.
14. Wu JJ, Stranix, BR, Milot G, et al. PL-100, a next generation protease inhibitor against drug resistant HIV: in vitro and in vivo metabolism. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract H-253, 2006.
15. Wu JJ, Dandache S, Stranix BR, et al. The HIV-1 protease inhibitor PL-100 has a high genetic barrier and selects a novel pattern of mutations. XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Spain, June 2006.
16. Gulnik S, Afonina E, Eissenstat M, et al. SPI-256, a highly potent HIV protease inhibitor with broad activity against MDR Strains. 13th CROI. Denver USA 2006 Abstract 501.
17. Afonina E, Gulnik S, Yokoe H, Erikson J. In Vitro Selection Strategy and Characterization of Resistance to a Novel Highly potent HIV Protease Inhibitor SPI-256 XV HIV Drug Resistance Workshop, 13-17 June 2006 Sitges, Spain.
18. Underwood M, Johns B, Sato A, et al. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. Fifth IAS Conference on HIV Treatment, Pathogenesis and Prevention, abstract WePeA098, 2009.
19. Lalezari J, Sloan L, Dejesus E, et al. Potent antiviral activity of S/ GSK1349572, a next generation integrase inhibitor (INI), in INI-naý v̈e HIV- 1-infected patients. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009). 19-22 July 2009. Cape Town, South Africa. Abstract TUAB105.
20. Jacobson JM, Thompson MA, Fischl MA, et al. Antiviral activity and tolerability of 5 mg/kg and 10 mg/kg doses of PRO 140, a humanised monoclonal antibody to CCR5. 48th ICAAC, 25-28 October 2008. Washington. Abstract H-1269a.
21. Thompson M, Lalezari J, Saag M, Jacobson J, Zingman B, Stambler N, D'Ambrosio P, Maddon P, Olson W, Morris S. Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February B-11 2009Abstract 571a.
22. Lalezari J, McCallister S, Gigliotti M, et al. A Phase 2 safety and efficacy study of bevirimat (BVM) in heavily treatment experienced HIV+ patients identifies the target Phase 3 study profile. 48th ICAAC, 25-28 October 2008. Washington. Abstract H-891.
23. McCallister S Lalezari J, Richmond G, et al. HIV-1 gag polymorphisms determine treatment response to beviramat (PA-457). Antivir Ther 2008; 13(Suppl. 3):A10 (abstract no. 8)
24. Klumpp K, Su G, Deval J, et al. 2'-deoxy-nucleoside analogs as potent dual inhibitors of HCV and HIV replication, with selectivity against other viral and human polymerases. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark. 22-26 April 2009.
25. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti- HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15:285-292.